Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Cash from Financing Activities (2018 - 2023)

Endonovo Therapeutics has reported Cash from Financing Activities over the past 12 years, most recently at $32765.0 for Q3 2023.

  • Quarterly results put Cash from Financing Activities at $32765.0 for Q3 2023, down 77.71% from a year ago — trailing twelve months through Sep 2023 was $606765.0 (down 29.61% YoY), and the annual figure for FY2022 was $593000.0, down 44.01%.
  • Cash from Financing Activities for Q3 2023 was $32765.0 at Endonovo Therapeutics, down from $187500.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ENDV hit a ceiling of $1.2 million in Q2 2019 and a floor of $32765.0 in Q3 2023.
  • Median Cash from Financing Activities over the past 5 years was $187500.0 (2023), compared with a mean of $261885.5.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 86.43% in 2020 and later skyrocketed 150.43% in 2022.
  • Endonovo Therapeutics' Cash from Financing Activities stood at $322237.0 in 2019, then tumbled by 36.79% to $203693.0 in 2020, then skyrocketed by 131.48% to $471500.0 in 2021, then crashed by 57.05% to $202500.0 in 2022, then plummeted by 83.82% to $32765.0 in 2023.
  • The last three reported values for Cash from Financing Activities were $32765.0 (Q3 2023), $187500.0 (Q2 2023), and $184000.0 (Q1 2023) per Business Quant data.